PL2739268T3 - Sposób i formulacja do inhalacji - Google Patents

Sposób i formulacja do inhalacji

Info

Publication number
PL2739268T3
PL2739268T3 PL11870462T PL11870462T PL2739268T3 PL 2739268 T3 PL2739268 T3 PL 2739268T3 PL 11870462 T PL11870462 T PL 11870462T PL 11870462 T PL11870462 T PL 11870462T PL 2739268 T3 PL2739268 T3 PL 2739268T3
Authority
PL
Poland
Prior art keywords
inhalation
formulation
Prior art date
Application number
PL11870462T
Other languages
English (en)
Inventor
Michelle Mcintosh
David Morton
Tomas SOU
Livesey OLERILE
Richard PRANKERD
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903049A external-priority patent/AU2011903049A0/en
Application filed by Monash University filed Critical Monash University
Publication of PL2739268T3 publication Critical patent/PL2739268T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
PL11870462T 2011-08-01 2011-11-07 Sposób i formulacja do inhalacji PL2739268T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011903049A AU2011903049A0 (en) 2011-08-01 Method and formulation for inhalation
EP11870462.6A EP2739268B1 (en) 2011-08-01 2011-11-07 Method and formulation for inhalation
PCT/AU2011/001430 WO2013016754A1 (en) 2011-08-01 2011-11-07 Method and formulation for inhalation

Publications (1)

Publication Number Publication Date
PL2739268T3 true PL2739268T3 (pl) 2019-07-31

Family

ID=47628537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11870462T PL2739268T3 (pl) 2011-08-01 2011-11-07 Sposób i formulacja do inhalacji

Country Status (20)

Country Link
US (3) US20140294969A1 (pl)
EP (1) EP2739268B1 (pl)
CN (1) CN103841960B (pl)
AU (1) AU2011374218B2 (pl)
BR (1) BR112014002646B1 (pl)
CA (1) CA2879317C (pl)
CY (1) CY1121373T1 (pl)
DK (1) DK2739268T3 (pl)
ES (1) ES2708218T3 (pl)
HR (1) HRP20190080T1 (pl)
HU (1) HUE041858T2 (pl)
LT (1) LT2739268T (pl)
MX (1) MX355833B (pl)
PL (1) PL2739268T3 (pl)
PT (1) PT2739268T (pl)
RS (1) RS58456B1 (pl)
SI (1) SI2739268T1 (pl)
TR (1) TR201900670T4 (pl)
WO (1) WO2013016754A1 (pl)
ZA (1) ZA201401526B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP2322180B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Diketopiperazine salts for drug delivery
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
US8636001B2 (en) 2008-06-13 2014-01-28 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2609954T3 (da) 2008-06-20 2022-02-14 Mannkind Corp Interaktivt apparat til realtidsafbildning af inhalationspræstationer
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2582421A1 (en) 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013016754A1 (en) * 2011-08-01 2013-02-07 Monash University Method and formulation for inhalation
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
MX2020009878A (es) * 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10183068B2 (en) 2014-05-16 2019-01-22 Stc.Unm Vaccination compositions, methods of making, and methods of use
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
US11589603B2 (en) 2015-09-11 2023-02-28 Abbott Laboratories Powdered nutritional product containing branched-chain amino acids and a sugar alcohol
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
PT108885B (pt) 2015-10-12 2019-02-13 Hovione Farm S A Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos
EP3532500A1 (en) 2016-10-31 2019-09-04 Vectura Limited Inhalable powder composition comprising il-13 antibody
KR20190126772A (ko) * 2017-03-07 2019-11-12 필립모리스 프로덕츠 에스.에이. 흡입 가능한 니코틴 제형, 및 이의 제조 및 사용 방법
CN111202722A (zh) * 2020-02-13 2020-05-29 江苏艾立康药业股份有限公司 一种洛匹那韦吸入干粉药物组合物及其制备方法
CN111202723A (zh) * 2020-02-15 2020-05-29 江苏艾立康药业股份有限公司 一种达芦那韦吸入干粉药物组合物及其制备方法
CN111202724A (zh) * 2020-02-16 2020-05-29 江苏艾立康药业股份有限公司 一种阿比朵尔吸入干粉药物组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0304540D0 (en) * 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
CA2555841A1 (en) * 2004-02-12 2005-09-01 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20090220435A1 (en) * 2005-07-27 2009-09-03 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
EP1986674A4 (en) * 2006-02-13 2009-11-11 Nektar Therapeutics PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
CA2701719A1 (en) * 2007-10-05 2009-04-09 President And Fellows Of Harvard College Dry powders of cellular material
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
CN101669925B (zh) * 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
WO2010033220A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2013016754A1 (en) * 2011-08-01 2013-02-07 Monash University Method and formulation for inhalation

Also Published As

Publication number Publication date
AU2011374218B2 (en) 2017-05-11
DK2739268T3 (en) 2019-02-25
EP2739268B1 (en) 2018-10-31
US20220152145A1 (en) 2022-05-19
CN103841960B (zh) 2017-07-07
US20170224762A1 (en) 2017-08-10
EP2739268A4 (en) 2015-03-25
BR112014002646A2 (pt) 2017-06-13
PT2739268T (pt) 2019-01-28
CA2879317A1 (en) 2013-02-07
MX2014001345A (es) 2014-11-13
TR201900670T4 (tr) 2019-02-21
WO2013016754A1 (en) 2013-02-07
SI2739268T1 (sl) 2019-05-31
ZA201401526B (en) 2017-09-27
AU2011374218A1 (en) 2014-03-20
BR112014002646A8 (pt) 2017-06-20
ES2708218T3 (es) 2019-04-09
CN103841960A (zh) 2014-06-04
RS58456B1 (sr) 2019-04-30
US20140294969A1 (en) 2014-10-02
CY1121373T1 (el) 2020-05-29
HRP20190080T1 (hr) 2019-03-22
LT2739268T (lt) 2019-03-25
MX355833B (es) 2018-05-02
CA2879317C (en) 2019-01-15
BR112014002646B1 (pt) 2021-09-14
US11065297B2 (en) 2021-07-20
EP2739268A1 (en) 2014-06-11
HUE041858T2 (hu) 2019-05-28

Similar Documents

Publication Publication Date Title
HRP20190080T1 (hr) Postupak i formulacija za inhaliranje
EP2729420A4 (en) METHOD AND APPARATUS FOR GLASS BENDING
GB201104694D0 (en) Apparatus and method
IL228557A0 (en) Solar absorbing formulations and related devices and methods
GB201102369D0 (en) Apparatus and method
GB201408236D0 (en) Composition and method
GB201122195D0 (en) Composition and method
ZA201307399B (en) Breathing apparatus
GB201122089D0 (en) Telecomunication apparatus and methods
SG11201408326TA (en) Preparation method for perfluoro-2-methyl-3-pentanone and intermediate
GB201105569D0 (en) Apparatus and methods
EP2762182A4 (en) PROTECTION DEVICE AND METHOD FOR THEIR USE
EP2719398A4 (en) MEDICAL TISSUE MARKER AND METHOD FOR MANUFACTURING THE SAME
GB201106433D0 (en) Composition and method
GB201104625D0 (en) Breathing apparatus
HK1200342A1 (zh) 鼻腔配方
IL231798A0 (en) method and preparation
GB201102361D0 (en) Apparatus and method
GB201106882D0 (en) Apparatus and method
AU2011903049A0 (en) Method and formulation for inhalation
AU2011904373A0 (en) Method and formulaiton for inhalation II
AU2011903839A0 (en) Inhalation device and method
GB201216531D0 (en) Method and means for maintaining posture
GB201117620D0 (en) Method and composition
GB201116421D0 (en) Composition and method